Search Results

You are looking at 91 - 100 of 975 items for :

  • Refine by Access: All Content x
Clear All

multiple port laparoscopic splenectomy in 10 dogs . Vet Surg. 2015 ; 44 ( suppl 1 ): 71 – 75 . doi: 10.1111/j.1532-950X.2014.12312.x 25522804 12. LeBlanc AK , Atherton M , Bentley RT , Veterinary Cooperative Oncology Group

Full access
in Journal of the American Veterinary Medical Association

. References 1. Dernell WS Ehrhart NP Straw RC , et al. Tumors of the skeletal system . In: Withrow SJ Vail DM , eds. Withrow and MacEwen's small animal clinical oncology . 4th ed. St Louis : Saunders Elsevier , 2007 ; 540 – 582 . 2

Full access
in American Journal of Veterinary Research

of dogs with malignant lymphoma . J Am Vet Med Assoc 1998 ; 213 : 985 – 990 . 15. Chun R Garrett LD Vail DM . Cancer chemotherapy . In: Withrow and MacEwen's small animal clinical oncology . 4th ed. Withrow SJ Vail DM , eds

Full access
in Journal of the American Veterinary Medical Association

Abstract

Objective—To determine the maximum tolerated dose and characterize the pharmacokinetic disposition of an orally administered combination of docetaxel and cyclosporin A (CSA) in dogs with tumors.

Animals—16 client-owned dogs with metastatic or advanced-stage refractory tumors.

Procedures—An open-label, dose-escalation, singledose, phase I study of docetaxel administered in combination with a fixed dose of CSA was conducted. Docetaxel (at doses of 1.5, 1.625, or 1.75 mg/kg) and CSA (5 mg/kg) were administered concurrently via gavage twice during a 3-week period. Plasma docetaxel concentrations were quantified by use of high-performance liquid chromatography, and pharmacokinetic disposition was characterized by use of noncompartmental analysis. Dogs' clinical signs and results of hematologic and biochemical analyses were monitored for evidence of toxicosis.

Results—No acute hypersensitivity reactions were observed after oral administration of docetaxel. Disposition of docetaxel was dose independent over the range evaluated, and pharmacokinetic variables were similar to those reported in previous studies involving healthy dogs, with the exception that values for clearance were significantly higher in the dogs reported here. The maximum tolerated dose of docetaxel was 1.625 mg/kg. Gastrointestinal signs of toxicosis were dose limiting.

Conclusions and Clinical Relevance—The absence of myelosuppression suggested that the docetaxelCSA combination may be administered more frequently than the schedule used. Further studies are warranted to evaluate combination treatment administered on a biweekly schedule in dogs with epithelial tumors.

Full access
in American Journal of Veterinary Research

Abstract

Objective—To evaluate response rate and duration of malignant melanomas in dogs treated with carboplatin.

Design—Retrospective study.

Animals—27 client-owned dogs with spontaneously occurring measurable malignant melanomas.

Procedure—Records of dogs with melanomas treated with carboplatin from October 1989 to June 2000 were reviewed. Carboplatin was administered IV at doses of 300 or 350 mg/m2 of body surface area. Response to treatment and evidence of drug toxicity were determined.

Result—Response to treatment could be evaluated in 25 dogs. Of those, overall response rate was 28%. One dog had a complete response, 6 (24%) dogs had a partial response (> 50% reduction in tumor burden). Median duration of partial response was 165 days. Eighteen dogs had stable disease (n = 9; 36%) or progressive disease (9; 36%). Response to treatment was significantly associated with carboplatin dose on a milligram per kilogram basis (15.1 mg/kg [6.9 mg/lb] of body weight vs 12.6 mg/kg [5.7 mg/lb]). Evidence of gastrointestinal toxicosis could be assessed in 27 dogs. Mean body weight of 5 dogs that developed gastrointestinal toxicosis was significantly less than that of 22 dogs without gastrointestinal toxicosis (9.9 kg [21.8 lb] vs 19.3 kg [42.5 lb]).

Conclusions and Clinical Relevance—Carboplatin had activity against macroscopic spontaneously occurring malignant melanomas in dogs and should be considered as an adjunctive treatment for microscopic local or metastatic tumors. Gastrointestinal toxicosis was associated with body weight. Because small dogs are more likely to have adverse gastrointestinal effects, gastrointestinal protectants should be considered for these patients. (J Am Vet Med Assoc 2001;218:1444–1448)

Full access
in Journal of the American Veterinary Medical Association

lymph node metastasis in dogs with OMM or OSCC. ABBREVIATIONS MLN Mandibular lymph node MRLN Medial retropharyngeal lymph node OMM Oral malignant melanoma OSCC Oral squamous cell carcinoma VSSO Veterinary Society of Surgical Oncology

Full access
in Journal of the American Veterinary Medical Association

to useful size (0.2 g) in only 7 days, resulting in minimal tumor-related disease. Recently, researchers at the University of Florida Comparative Oncology Laboratory investigated the in vitro radiosensitivity of canine osteosarcoma cells. 23 Through

Full access
in American Journal of Veterinary Research

services, to have been cited at least 68 times. These are only 2 examples of how outdated references continue to be cited in the veterinary oncology literature, primarily because the literature has not been updated with newer, more accurate epidemiological

Full access
in Journal of the American Veterinary Medical Association

Abstract

Objective—To determine toxic effects of streptozocin given in combination with a diuresis protocol in dogs and establish whether streptozocin is efficacious in treatment of pancreatic islet cell tumors in dogs.

Design—Retrospective study.

Animals—17 dogs.

Procedure—Medical records were reviewed to obtain information regarding signalment, tumor stage and staging tests performed, number of streptozocin treatments, adverse effects, results of biochemical and hematologic monitoring during streptozocin treatment, tumor dimensions, duration of normoglycemia, and date of death, when applicable. Dogs were compared with a historical control group of 15 dogs treated surgically and medically.

Results—58 treatments were administered to the 17 dogs. Only 1 dog developed azotemia. Serum alanine aminotransferase activity increased in some dogs but decreased when treatment was discontinued. Hematologic toxicoses were rare. Vomiting during administration was uncommon but occasionally severe. Two dogs developed diabetes mellitus after receiving 5 doses. Median duration of normoglycemia for 14 dogs with stage-II or -III insulinoma treated with streptozocin was 163 days (95% confidence interval, 16 to 309 days), which was not significantly different from that for the control dogs (90 days; 95% confidence interval, 0 to 426 days). Two dogs had rapid resolution of paraneoplastic peripheral neuropathy, and 2 others had measurable reductions in tumor size.

Conclusions and Clinical Relevance—Results suggest that streptozocin can be administered safely to dogs at a dosage of 500 mg/m2, IV, every 3 weeks when combined with a protocol for induction of diuresis and may be efficacious in the treatment of dogs with metastatic pancreatic islet cell tumors. (J Am Vet Med Assoc 2002;221:811–818)

Full access
in Journal of the American Veterinary Medical Association

Abstract

OBJECTIVE

To compare erythrocyte recovery by a cell salvage device between swab-washing by manual agitation or filtration.

SAMPLE

12 recently expired units of canine packed RBCs.

PROCEDURE

The packed RBC units underwent quality analysis before donation from a pet blood bank. Each unit was volume-expanded with anticoagulant and subsequently divided into 2 equal aliquots used to soak surgical swabs before washing. Two different swab-washing techniques were evaluated—standard swab-washing–manual agitation (SW-MA) and swab-washing–filtration (SW-F)—with a novel prototype device. The resulting bloody fluid was processed using the Cell Saver Elite Autotransfusion System (Haemonetics). The volume, manual PCV, CBC, and RBC mass, calculated as the product of the volume and PCV, were measured before and after salvaging. Last, the RBC mass recovery was recorded as a percentage.

RESULTS

The RBC mass recovered from SW-MA and SW-F averaged 85.73% and 83.99%, respectively. There was no significant difference in RBC recovery between the 2 methods (P = .52).

CLINICAL RELEVANCE

SW-MA and SW-F recovered a similar quantity of RBCs from blood-soaked swabs in an ex vivo setting.

Open access
in American Journal of Veterinary Research